Analyst Research

Report Title Price
Provider : Reuters Investment Profile
$20.00
Provider : Reuters Investment Profile
$20.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Shanghai Fosun Pharmaceutical Group Co Ltd's Sub-subsidiary to Sell Assets to SELLAS Clinicals Holding AG


Sunday, 20 Oct 2013 08:00pm EDT 

Shanghai Fosun Pharmaceutical Group Co Ltd announced that its Chongqing-based pharmaceutical research sub-subsidiary will sell intellectual properties as well as related development, commercialization, sales and license rights on chemical A (DPP4 inhibitor) and chemical B (receptor inhibitor) owned by the sub-subsidiary and its subsidiary, for approximately EUR 388 million to SELLAS Clinicals Holding AG.